TRex Bio (NASDAQ:TRXB – Get Free Report) released its quarterly earnings data on Friday. The company reported ($10.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($9.37), Zacks reports.
TRex Bio Stock Performance
Shares of TRXB traded down $0.43 on Friday, reaching $13.67. The stock had a trading volume of 62,668 shares, compared to its average volume of 90,289. TRex Bio has a twelve month low of $12.50 and a twelve month high of $16.56.
Analyst Ratings Changes
A number of research firms have recently weighed in on TRXB. Cantor Fitzgerald assumed coverage on shares of TRex Bio in a research note on Tuesday, November 3rd. They set an “overweight” rating on the stock. Evercore started coverage on shares of TRex Bio in a report on Tuesday, November 3rd. They issued a “strong-buy” rating for the company. Stifel Nicolaus started coverage on shares of TRex Bio in a research note on Tuesday, November 3rd. They issued a “buy” rating and a $39.00 price objective for the company. Zacks Research initiated coverage on shares of TRex Bio in a report on Tuesday, November 3rd. They set a “hold” rating on the stock. Finally, Wedbush assumed coverage on shares of TRex Bio in a research report on Monday, November 2nd. They set an “outperform” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $29.67.
View Our Latest Report on TRXB
Insider Transactions at TRex Bio
In other news, major shareholder Alexandria Venture Investments acquired 178,571 shares of TRex Bio stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the acquisition, the insider owned 1,346,501 shares in the company, valued at $18,851,014. This trade represents a 15.29% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
TRex Bio Company Profile
We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.
Read More
- Five stocks we like better than TRex Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for TRex Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRex Bio and related companies with MarketBeat.com's FREE daily email newsletter.
